Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 179-184

  Roberts, Stuart K ^a,ac   Mitchell, Joanne ^a   Leung, Reynold ^d   Booth, David ^d   Bollipo, Steven ^h,n   Ostapowicz, George ⁱ   Sloss, Andrew ^j,n   McCaughan, Geoff ^e   Dore, Gregory J ^f,o   Thompson, Alexander ^b   Crawford, Darrell ⁿ   Sievert, William ^c,ad   Weltman, Martin ^g   Cheng, Wendy ^l,n   George, Jacob ^d   Angus, Peter ^m   Chu, Geoff ⁿ   Cornwall, Mark ⁿ   Douglas, Mark ⁿ   Hallinan, Richard ⁿ   Haque, Mazhar ^p   Hawkin, Glenn ⁿ   Jackson, Hugh ^q   Johnson, Richard ⁿ   Kronborg, Ian ^r   Lee, Alice ^s   Leggett, Barbara ^t   Mire, Marc Le ^u   Levy, Miriam ^v   Lubel, John ^w   MacQuillan, Gerry ^x   Masson, John ^y   McDonald, Jenny ⁿ   McGarity, Bruce ⁿ   Mollison, Lindsay ^z   Nicoll, Amanda ^aa   Ombiga, John ⁿ   Riordan, Stephen ^ab   Strasser, Simone ^e   Thompson, Alex ^b   Watson, Jon ^ae   Wenman, John ^af   Wigg, Alan ^ag   Zekry, Amany ^ah   more..

^a The Alfred   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g NEPEAN HOSPITAL   (Australia)

^h JOHN HUNTER HOSPITAL   (Australia)

ⁱ GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^j Nambour Hospital   (Australia)

^k GREENSLOPES PRIVATE HOSPITAL   (Australia)

^l ROYAL PERTH HOSPITAL   (Australia)

^m AUSTIN HOSPITAL   (Australia)

ⁿ St Vincent's Hospital ^*

^o ST VINCENT S HOSPITAL   (Australia)

^p Mater Hospital   (Australia)

^q Hobart Hospital   (Australia)

^r WESTERN HOSPITAL   (Australia)

^s ANZAC Research Institute   (Australia)

^t ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^u ROYAL ADELAIDE HOSPITAL   (Australia)

^v LIVERPOOL HOSPITAL   (Australia)

^w BOX HILL HOSPITAL   (Australia)

^x SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^y TOWNSVILLE HOSPITAL   (Australia)

^z FREMANTLE HOSPITAL   (Australia)

^aa ROYAL MELBOURNE HOSPITAL   (Australia)

^ab PRINCE OF WALES HOSPITAL   (Australia)

^ac ALFRED HOSPITAL   (Australia)

^ad MONASH MEDICAL CENTRE   (Australia)

^ae GEELONG HOSPITAL   (Australia)

^af Monash Medical Centre ^*  (Australia)

^ag Flinders Private Hospital   (Australia)

^ah ST GEORGE HOSPITAL   (Australia)

more..

Author keywords

Chronic hepatitis C; HCV genotype 1; IFN 3 (Interleukin 28B)

Indexed keywords

INTERFERON; INTERFERON LAMBDA 3; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASIAN; AUSTRALIA; CAUCASIAN; DRUG MEGADOSE; ETHNIC GROUP; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PACIFIC ISLANDER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY;

CHRONIC HEPATITIS C; HCV GENOTYPE 1; IFN-Λ3 (INTERLEUKIN 28B);

ASIA; AUSTRALIA; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; PACIFIC ISLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84897625092     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12424     Document Type: Article

References (20)

1. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
2. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
3. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
4. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
5. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
6. Kitson MT, Dore GJ, George J etal. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J. Hepatol. 2013; 58: 467-472.
7. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
8. Liu C-H, Kao J-H. Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J. Gastroenterol. Hepatol. 2011; 26: 1348-1353.
9. Gidding HF, Topp L, Middleton M etal. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J. Gastroenterol. Hepatol. 2009; 24: 1648-1654.
10. Roberts SK, Weltman MD, Crawford DHG etal. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50: 1045-1055.
11. Lin CY, Chen JY, Lin TN etal. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 2011; 6: e18322.
12. Liao XW, Ling Y, Li XH etal. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir. Ther. 2011; 16: 141-147.
13. Huang C-F, Dai C-Y, Huang J-F, Chuang W-L, Yu M-L. Linkage of the hepatitis V virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011; 53: 367-368.
14. Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, Lee JH. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J. Gastroenterol. Hepatol. 2011; 26: 1374-1379.
15. Ochi H, Maekawa T, Abe H etal. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J. Gen. Virol. 2011; 92: 1071-1081.
16. Hsu CS, Hsu SJ, Chen HC etal. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl Acad. Sci. U. S. A. 2011; 108: 3719-3724.
17. Huang CF, Yeh ML, Huang JF etal. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res. 2012; 93: 239-244.
18. Cooper CL, Bailey RJ, Bain VG etal. Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can. J. Gastroenterol. 2008; 22: 677-680.
19. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C etal. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
20. Fischer J, Böhm S, Scholz M etal. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-1710.